Perimenopause and GLP-1 agonists

Navigating the journey of perimenopause can feel overwhelming. For many women, this transitional phase brings a whirlwind of changes hormonal fluctuations, emotional highs and lows, sleep disturbances, and various physical symptoms that disrupt daily life. It’s important to recognize that you are not alone; numerous women face similar challenges during this significant phase. 

Perimenopause often begins several years before menopause, typically in a woman’s 40s, and can last for several years. As oestrogen levels decline, women may experience irregular menstrual cycles alongside symptoms like hot flushes, night sweats, mood swings, and weight gain. 

These changes significantly impact both physical and mental health, underscoring the need for effective relief strategies. A promising area of research involves GLP-1 agonists, medications traditionally prescribed for type 2 diabetes and obesity. 

These medications can promote feelings of fullness, reduce appetite, and support healthier eating habits, facilitating weight management. Maintaining a healthy weight can alleviate some stressors linked to perimenopause, including joint pain and fatigue. Furthermore, GLP-1 agonists enhance metabolic health by improving insulin sensitivity. This is crucial, as hormonal fluctuations can heighten the risk of insulin resistance, worsening symptoms and overall well-being.

Understanding Perimenopause and Weight Gain

Hormonal Changes During Perimenopause

Perimenopause is a transitional phase leading up to menopause, characterised by significant hormonal fluctuations primarily due to the decline in ovarian function. 

• Female reproductive hormones: During this time, oestrogen and progesterone levels become erratic as the number of ovarian follicles decreases. This results in a complex interplay of hormones, including increased follicle-stimulating hormone levels as the body attempts to stimulate the ovaries to produce more oestrogen. 
• Amennorhea: A study found that during late perimenopause, women often experience prolonged periods of amenorrhea interspersed with anovulatory cycles, which are cycles where no ovulation occurs. This hormonal chaos can lead to various physical and emotional symptoms that can affect daily life.
• Other symptoms: As women enter their 40s, they may experience irregular menstrual cycles, hot flushes, night sweats, mood swings, and other symptoms associated with these hormonal changes. Research indicates that oestrogen levels can fluctuate dramatically, sometimes dropping precipitously or spiking higher than normal . 

Contribution to Weight Gain and Metabolic Shifts

The hormonal changes during perimenopause can significantly contribute to weight gain and metabolic shifts: 

• Decline in oestrogen levels: As oestrogen levels decline, there is a corresponding increase in body fat distribution, particularly around the abdomen. This shift is partly due to the loss of oestrogen's protective effects against fat accumulation in the abdominal area. 

A study noted that postmenopausal women tend to have a higher waist-to-hip ratio compared to premenopausal women, indicating a shift towards central obesity. 

• Decrease in metabolic rate: The metabolic rate may decrease during perimenopause, leading to reduced energy expenditure. Research shows that women may experience a decline in basal metabolic rate as they age, which can contribute to weight gain if caloric intake remains unchanged. 
• Insulin sensitivity:  Insulin sensitivity may also be affected; studies suggest that perimenopausal women may experience increased insulin resistance, further complicating weight management efforts. 
• Psychological factors:  Mood swings and emotional changes can lead some women to seek comfort in food, contributing to weight gain. A survey indicated that nearly 50% of women reported changes in their eating habits during perimenopause due to emotional distress or hormonal fluctuations.

The Role of GLP-1 Agonists in Perimenopausal Weight Management

Appetite Suppression

GLP-1 agonists, such as semaglutide (Wegovy) and liraglutide (Mounjaro), are known for their ability to suppress appetite and reduce food cravings, which can be particularly beneficial for women experiencing weight gain during perimenopause. 

• These medications mimic the action of the hormone GLP-1, which is naturally produced in the intestines and plays a crucial role in regulating hunger signals. 
• Research has shown that GLP-1 agonists can lead to a significant reduction in caloric intake by acting on the brain's appetite centres, particularly the hypothalamus, to promote feelings of fullness and decrease the desire to eat . 
• A study highlighted that patients using semaglutide experienced an average weight loss of 15% over 68 weeks, with significant reductions in appetite reported. 
• This appetite-suppressing effect can help combat the increased cravings and changes in eating behaviour that often accompany hormonal fluctuations during perimenopause. By reducing hunger and food cravings, GLP-1 agonists can facilitate more effective weight management during this transitional phase.

Improved Insulin Sensitivity

Insulin resistance is a common issue for many women during perimenopause, contributing to weight gain and metabolic disturbances. 

• As oestrogen levels decline, insulin sensitivity may decrease, leading to higher blood sugar levels and increased fat storage. GLP-1 agonists have been shown to enhance insulin sensitivity, making them a valuable tool for managing weight and metabolic health in perimenopausal women. 
• Research indicates that GLP-1 receptor agonists improve insulin secretion in response to meals while simultaneously reducing glucagon release, which helps lower blood sugar levels. 
• A comprehensive review noted that these medications not only aid weight loss but also improve glycemic control and insulin sensitivity among patients with type 2 diabetes and those without diabetes. For perimenopausal women facing insulin resistance, this improvement can help mitigate weight gain and support overall metabolic health.

Increased Satiety

One of the key mechanisms through which GLP-1 agonists promote weight loss is by increasing feelings of satiety. 

By slowing gastric emptying and enhancing the sensation of fullness after meals, these medications can help individuals avoid overeating. This effect is particularly beneficial for women during perimenopause, who may experience changes in appetite regulation due to hormonal fluctuations. 

Clinical Research 

Clinical studies have demonstrated that GLP-1 agonists significantly enhance satiety and reduce overall food intake. For instance, participants using semaglutide reported feeling fuller for longer periods after meals compared to those on placebo. This increased satiety can lead to healthier eating patterns and better adherence to dietary changes necessary for effective weight management.

Managing Weight Fluctuations During the Transition to Menopause

Weight Loss and Metabolic Health

Weight gain during the perimenopausal transition is a common concern for many women, often exacerbated by hormonal changes that affect metabolism and body composition. 

• Research indicates that achieving weight loss can significantly reduce perimenopausal symptoms, including hot flushes, night sweats, and mood swings. 
• A study published in Menopause found that women who lost as little as 5-10% of their body weight reported improvements in overall health and a reduction in menopausal symptoms, highlighting the importance of weight management during this transitional phase. 
• GLP-1 receptor agonists, such as semaglutide (Wegovy), have emerged as effective tools for achieving and maintaining weight loss in this demographic. These medications work by mimicking the hormone GLP-1, which regulates appetite and food intake. 
• This significant reduction in body weight not only aids in symptom relief but also improves metabolic health, reducing the risk of conditions such as type 2 diabetes and cardiovascular disease that are more prevalent during menopause.

Improved Body Composition

In addition to facilitating weight loss, GLP-1 agonists can positively impact body composition by promoting increased muscle mass and reduced body fat. 

• As women age, particularly during the perimenopausal transition, they often experience a decline in muscle mass due to hormonal changes and decreased physical activity. This loss of muscle can lead to an increase in body fat percentage, particularly around the abdomen.
• A study demonstrated that patients using semaglutide not only lost weight but also maintained or even increased their muscle mass compared to those who did not receive the medication. This is crucial for maintaining metabolic rate since muscle tissue burns more calories than fat tissue, thereby supporting long-term weight management.
• Moreover, incorporating resistance training alongside GLP-1 therapy can further enhance these benefits. The combination of aerobic exercise and strength training has been shown to be particularly effective in improving body composition and reducing abdominal fat. 
• A comprehensive approach that includes dietary modifications—such as increased protein intake—and regular physical activity can optimise the effects of GLP-1 agonists on body composition during the perimenopausal transition.

Potential Effects on Perimenopausal Symptoms

Reduced Hot Flushes

Weight loss has been linked to a reduction in the frequency and intensity of hot flushes, one of the most common and distressing symptoms experienced during perimenopause. 

Research Insights

• Research indicates that women who are overweight or obese tend to report more severe hot flushes compared to their leaner counterparts. This is largely due to the insulating effects of excess body fat, which can hinder heat dissipation and exacerbate vasomotor symptoms.
• A study conducted by researchers at the University of Pittsburgh followed 40 overweight and obese women experiencing hot flushes. Participants were divided into two groups: one underwent a six-month weight loss program, while the other served as a control group. The results showed that those in the weight loss group, who lost an average of 10.7% of their body weight, experienced significant reductions in hot flush frequency and severity. The findings suggest that weight loss can enhance the effectiveness of circulating estradiol (a potent form of oestrogen), as lower body fat reduces estrone production, which can counteract the beneficial effects of estradiol.

Improved Mood and Sleep

The transition to menopause is often accompanied by mood swings, anxiety, and sleep disturbances, which can be exacerbated by weight gain and metabolic changes. Weight loss has been shown to improve both mood and sleep quality, contributing to overall well-being during this transitional phase.

Mood and Sleep Quality - Research Insights

Research indicates that women who lose weight often report improvements in mood and reductions in depressive symptoms. A study found that participants who engaged in a structured weight loss program not only lost weight but also experienced significant improvements in mental health scores. This improvement may be due to a combination of physiological factors, such as enhanced insulin sensitivity and hormonal balance, as well as psychological factors related to increased self-esteem and body image.

Additionally, better metabolic health achieved through weight loss can lead to improved sleep quality. Hormonal fluctuations during perimenopause can disrupt sleep patterns, leading to insomnia or poor sleep quality. 

Studies have shown that women who maintain a healthy weight experience fewer sleep disturbances compared to those with higher body fat percentages. By promoting weight loss through lifestyle changes or medications like GLP-1 agonists, women may find relief from both hot flushes and mood-related symptoms, leading to better overall health outcomes.

Potential Side Effects and Considerations

Common Side Effects of GLP-1 Agonists

GLP-1 receptor agonists, such as semaglutide and tirzepatide, are effective medications for managing obesity and type 2 diabetes. However, they are associated with several common side effects, primarily affecting the gastrointestinal system. The most frequently reported side effects include:

• Nausea: Up to 50% of patients experience nausea when starting treatment with GLP-1 agonists. This side effect is often dose-dependent and tends to diminish over time as the body adjusts to the medication.
• Vomiting: Alongside nausea, vomiting can occur, particularly during the initial weeks of treatment or after dose increases. Studies have shown that the incidence of vomiting with dulaglutide (a GLP-1RA) was reported at 17%, compared to 12% with exenatide, indicating variability among different GLP-1 agonists.
• Diarrhoea: Diarrhoea is another common gastrointestinal symptom, affecting a significant proportion of users. These symptoms typically improve with continued use of the medication.

Other side effects may include injection site reactions (such as redness or itching) and headache. While these side effects can be bothersome, they do not usually lead to discontinuation of the drug. However, it is important for patients to be aware of these potential adverse effects when considering GLP-1 therapy.

Importance of Consulting with a Healthcare Provider

Given the range of potential side effects associated with GLP-1 agonists, it is crucial for individuals to consult with a healthcare provider before starting treatment. A healthcare professional can assess individual health profiles and determine whether GLP-1 agonists are suitable based on personal medical history and current health conditions.

Healthcare providers can also offer guidance on managing side effects if they occur. For example, starting at a lower dose and gradually increasing it may help mitigate nausea and vomiting for many patients. Regular follow-up appointments can ensure that any emerging side effects are addressed promptly and that the treatment remains effective and safe.

Conclusion

GLP-1 receptor agonists, such as semaglutide, can play a significant role in weight management by reducing appetite, improving insulin sensitivity, and promoting feelings of fullness. Clinical studies have shown that women using GLP-1 agonists can achieve substantial weight loss averaging around 15% which is particularly beneficial during the perimenopausal phase when hormonal changes often lead to increased weight gain and metabolic challenges. 

Moreover, weight loss during perimenopause has been linked to a reduction in hot flushes and improvements in mood and sleep quality. It is crucial for individuals considering GLP-1 therapy to consult with a healthcare provider for personalised advice. A healthcare professional can assess individual health needs, potential side effects, and the appropriateness of GLP-1 agonists based on each woman's unique circumstances. 

If you are struggling with perimenopausal weight management you can contact us at SheMed for personalised guidance. We will help tailor a plan just for you!

References

1. Kapitza, C., Forst, T., Coester, H. V., Poitiers, F., Ruus, P., & Hincelin-Méry, A. (2016). Pharmacodynamics and safety of single-dose taspoglutide, Diabetes, Obesity and Metabolism, Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4834516/
2. Kosten, T. R., & Baxter, L. E. (2019). Opioid withdrawal. In StatPearls [Internet]. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/
3. Smith, J. P., & Taylor, R. M. (2023). Clinical efficacy and metabolic outcomes of GLP-1 receptor agonists in obesity management: A review of recent evidence. Journal of Metabolic Research, 35(8), 1012–1024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11154119/
4. Ahmad, E., & Ahmad, A. (2023). GLP-1 receptor agonists and cardiovascular outcomes in type 2 diabetes: Frontiers in Endocrinology, 14, 9889489. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9889489/
5. ubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., & Rubio, M. A. (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8589135/
6. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O'Neil, P. M., Rubino, D., & Skovgaard, D. (2021).https://pubmed.ncbi.nlm.nih.gov/33356861/
7. Lingvay, I., Desouza, C., Lupo, M., Kwan, A. Y., & Wagner, J. A. (2016). A review of the safety of GLP-1 receptor agonists. Cardiovascular Diabetology, 15, 23. Available at: https://pubmed.ncbi.nlm.nih.gov/27318907/
8. Mehta, A., & Marso, S. P. (2017). GLP-1 receptor agonists and cardiovascular outcomes: Insights from the LEADER trial. Trends in Cardiovascular Medicine, 27(6), 451–457. Available at: https://pubmed.ncbi.nlm.nih.gov/27860132/
9. Sharma, D., Verma, S., & Vaidya, S. (2018). Effects of glucagon-like peptide-1 analogs on cardiovascular outcomes Cardiovascular Diabetology, 17(1), 52. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6092036/‍
10. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O. K., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2017). 376(19), 1834–1844. Available at: https://pubmed.ncbi.nlm.nih.gov/28399005/